# PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

> **NCT02933255** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** PROSTVAC-V/F
- **DRUG:** Nivolumab
- **PROCEDURE:** Prostatectomy
- **PROCEDURE:** Biopsy
- **DRUG:** Tylenol

## Key facts

- **NCT ID:** NCT02933255
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-18
- **Primary completion:** 2023-06-20
- **Final completion:** 2023-12-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02933255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02933255, "PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02933255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*